Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MasterCard Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.18 (market cap $29.97B), while MasterCard Inc trades at $567.76 (market cap $490.33B). The key difference: MasterCard Inc is far larger — about 16.4× Alnylam Pharmaceuticals, Inc.'s market cap, and MasterCard Inc pays a 0.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MA | |
|---|---|---|
Market Cap | $29.97B | $490.33B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $598.96 |
52-Week Low | $205.48 | $471.55 |
Enterprise Value | $27.93B | $503.36B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $227.12, up 2.68% in the last 24 hours, but technical indicators signal a bearish trend with resistance near $229. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with a net income of $313.75M, though recent Q2 2026 earnings missed estimates. Multiple law firms are investigating potential securities fraud, adding to negative sentiment.
Outlook is mixed: analyst consensus remains bullish with a $370.07 price target, but risks include ongoing legal probes, earnings volatility, and high valuation multiples. The stock faces near-term pressure from bearish technicals and investor caution despite solid fundamental progress.
Mastercard (MA) trades at $559.73, down 0.3%, with a bullish technical signal and strong fundamentals. Recent quarters show consistent EPS beats, with Q2 2026 actual EPS of $5.04 exceeding the $4.77 estimate. Revenue grew to $32.79B in 2025, with a net income margin of 46.34%. Institutional buying is evident from recent 13F filings, such as Eagle Strategies increasing holdings by 498.6% in Q1 2026 (SEC filing, April 11, 2026).
The outlook is positive, supported by a consensus price target of $660.85 and 79% buy ratings. Opportunities include expansion in digital payments and AI initiatives, but risks involve competition from stablecoins and regulatory scrutiny. Earnings growth and high profitability drive upside potential, though valuation multiples like a P/E of 30.79 warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
